Physical Address

304 North Cardinal St.
Dorchester Center, MA 02124

Right Ventricular Pacing–Related Cardiomyopathy


Age Gender Occupation Working Diagnosis
62 Years Male Physician Progressive Left Ventricular Dysfunction Resulting from Chronic Right Ventricular Pacing

History

A 62-year-old nonsmoking man was referred for upgrade of his dual-chamber pacing system to a cardiac resynchronization therapy (CRT) pacing system. The dual-chamber pacing system had been implanted 4 years earlier. The initial indication for cardiac pacing was complete heart block that developed roughly 8 hours after radiofrequency ablation of the cavotricuspid isthmus for the treatment of symptomatic atrial flutter. The components of this initial pacing system were a St. Jude Medical Victory XL DR 5816, a Medtronic bipolar screw-in atrial lead 5568-53, and a Medtronic bipolar screw-in ventricular lead 4076-58. At the time the initial pacing system was implanted, his left ventricular size and ejection fraction (60%-65%) were normal. On device interrogation he routinely paced more than 99% of the time.

The patient developed fatigue, exercise intolerance, and dyspnea on exertion. After atrial flutter ablation, he was started on flecainide for symptomatic paroxysmal atrial fibrillation. His other pertinent medical history included dyslipidemia and hypertension. His ejection fraction was reassessed. His left ventricular ejection fraction by radionuclide angiogram was 38%. An ischemic cause for his cardiomyopathy was ruled out by elective coronary angiography.

Current Medications

The patient’s daily medications were aspirin 81 mg, cetirizine 10 mg, dutasteride 0.5 mg, enalapril 5 mg, escitalopram 10 mg, flecainide 50 mg, hydrochlorothiazide 25 mg, and simvastatin 80 mg.

Comments

Flecainide is generally avoided in patients with conduction system disease. Flecainide slows conduction that can further widen the QRS complex from baseline, leading for further ventricular dyssynchrony. Flecainide also should be avoided in patients with coronary or structural heart disease because of the increased risk for malignant tachyarrhythmias. Flecainide was discontinued in this patient for these reasons.

Current Symptoms

The patient’s symptoms included fatigue, exercise intolerance, and dyspnea on exertion.

Physical Examination

  • BP/HR: 140/94 mm Hg/60 bpm

  • Height/weight: 180.0 cm/100.60 kg

  • Neck veins: No jugulovenous pressure distention

  • Lungs/chest: Normal breath sounds bilaterally

  • Heart: Regular rate and rhythm with wide paradoxical splitting of the second heart sound (S 2 ); faint murmur of tricuspid regurgitation

  • Abdomen: Soft, nontender, nondistended

  • Extremities: Normal

Laboratory Data

  • Hemoglobin: 14.7 g/dL

  • Hematocrit/packed cell volume: 43.2

  • Mean corpuscular volume: 91.1 fL

  • Platelet count: 212 × 10 3 /µL

  • Sodium: 143 mmol/L

  • Potassium: 4.1 mmol/L

  • Creatinine: 1.1 mg/dL

Electrocardiogram

You're Reading a Preview

Become a Clinical Tree membership for Full access and enjoy Unlimited articles

Become membership

If you are a member. Log in here

Related Posts